Platelet perturbations in diabetes

Implications for cardiovascular disease risk and treatment

Shiny Mathewkutty, Darren K McGuire

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications. Despite advances in evidence-based therapies for cardiovascular disease risk modification, many of which are especially effective among patients with DM, there remains a residual degree of cardiovascular disease risk associated with DM, yielding opportunity for continued clinical advances. Given the myriad perturbations of platelet function associated with DM, improvements in antiplatelet therapies hold particular promise for this high-risk population of patients, with emerging data from ex vivo assessments and clinical outcomes trials providing a basis of support for this concept.

Original languageEnglish (US)
Pages (from-to)541-549
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Volume7
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Diabetes Mellitus
Cardiovascular Diseases
Blood Platelets
Type 2 Diabetes Mellitus
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials
Population

Keywords

  • Antiplatelet therapy
  • Cardiovascular disease
  • Diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Platelet perturbations in diabetes : Implications for cardiovascular disease risk and treatment. / Mathewkutty, Shiny; McGuire, Darren K.

In: Expert Review of Cardiovascular Therapy, Vol. 7, No. 5, 05.2009, p. 541-549.

Research output: Contribution to journalArticle

@article{c47241bcff784425ba6c15dbbdb2d922,
title = "Platelet perturbations in diabetes: Implications for cardiovascular disease risk and treatment",
abstract = "The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications. Despite advances in evidence-based therapies for cardiovascular disease risk modification, many of which are especially effective among patients with DM, there remains a residual degree of cardiovascular disease risk associated with DM, yielding opportunity for continued clinical advances. Given the myriad perturbations of platelet function associated with DM, improvements in antiplatelet therapies hold particular promise for this high-risk population of patients, with emerging data from ex vivo assessments and clinical outcomes trials providing a basis of support for this concept.",
keywords = "Antiplatelet therapy, Cardiovascular disease, Diabetes mellitus",
author = "Shiny Mathewkutty and McGuire, {Darren K}",
year = "2009",
month = "5",
doi = "10.1586/erc.09.30",
language = "English (US)",
volume = "7",
pages = "541--549",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Platelet perturbations in diabetes

T2 - Implications for cardiovascular disease risk and treatment

AU - Mathewkutty, Shiny

AU - McGuire, Darren K

PY - 2009/5

Y1 - 2009/5

N2 - The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications. Despite advances in evidence-based therapies for cardiovascular disease risk modification, many of which are especially effective among patients with DM, there remains a residual degree of cardiovascular disease risk associated with DM, yielding opportunity for continued clinical advances. Given the myriad perturbations of platelet function associated with DM, improvements in antiplatelet therapies hold particular promise for this high-risk population of patients, with emerging data from ex vivo assessments and clinical outcomes trials providing a basis of support for this concept.

AB - The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications. Despite advances in evidence-based therapies for cardiovascular disease risk modification, many of which are especially effective among patients with DM, there remains a residual degree of cardiovascular disease risk associated with DM, yielding opportunity for continued clinical advances. Given the myriad perturbations of platelet function associated with DM, improvements in antiplatelet therapies hold particular promise for this high-risk population of patients, with emerging data from ex vivo assessments and clinical outcomes trials providing a basis of support for this concept.

KW - Antiplatelet therapy

KW - Cardiovascular disease

KW - Diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=68949212906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949212906&partnerID=8YFLogxK

U2 - 10.1586/erc.09.30

DO - 10.1586/erc.09.30

M3 - Article

VL - 7

SP - 541

EP - 549

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 5

ER -